Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Merck & Co (NYSE:MRK) announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating Keytruda for the potential adjuvant treatment in a subset of patients with renal cell carcinoma (RCC).
- The trial included RCC patients at intermediate-high or high risk of recurrence following nephrectomy (surgical removal of a kidney) or following nephrectomy and resection of metastatic lesions.
- The results will be presented at the virtual American Society of Clinical Oncology meeting.
- In patients with clear-cell renal cell carcinoma, Keytruda treatment after surgery slashed the risk of the disease returning or death by 32% compared with placebo.
- At the two-year mark, 77.3% of patients who got Keytruda in Phase 3 Keynote-564 trial remained alive and disease-free, compared to 68% in the placebo group.
- Overall survival (OS) was too early to determine at the data cutoff. Still, the company did have a “favorable trend” in the early readout, with Keytruda cutting the risk of death by 46% over placebo.
- However, the median disease-free survival data were immature at this point.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: MRK shares closed at $73.91 on Thursday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!